Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 229

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 229
---
 is qualified in its entirety by the terms and conditions of the Sponsor Support Agreement, a copy of which is attached hereto as Annex D and is incorporated herein by reference.

PIPE Subscription Agreement

Concurrently with the execution of the Business Combination Agreement, ParentCo and Iris have entered into the PIPE Equity Subscription Agreement with the PIPE Investor pursuant to which the PIPE Investor has committed to purchase the PIPE Shares, for an aggregate purchase price of $15,000,000. The obligations to consummate the transaction contemplated by the PIPE Equity Subscription Agreement are conditioned upon, among other things, customary closing conditions and the consummation of the transactions contemplated by the Business Combination Agreement. The parties to the PIPE Equity Subscription Agreement entered into amendments to such agreement on August 14, 2023, March 9, 2024, July 23, 2024, August 16, 2024 and December 26, 2024 to, among other things, extend the date the PIPE Investor can terminate such agreement and on October 31, 2024, to reduce the PIPE Investor’s investment commitment to $15 million.

In connection with the PIPE Equity Investment, ParentCo will grant the PIPE Investor certain customary registration rights as described under “ Registration Rights Agreement ”. The PIPE Shares have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), and will be issued in reliance on the availability of an exemption from such registration.

The foregoing description of the PIPE Equity Subscription Agreement does not purport to be complete and is qualified in its entirety by the terms and conditions of the PIPE Equity Subscription Agreement, a copy of which is attached hereto as Annex E , and is incorporated herein by reference.

<div align='center'>105</div>

TABLE OF CONTENTS

Sponsor Forfeiture Agreement

Concurrently with the execution of the Business Combination Agreement, the Sponsor and Iris entered into a Sponsor Forfeiture Agreement (the “Forfeiture Agreement”), pursuant to which the Sponsor agreed to forfeit 4,177,778 private placement warrants effective immediately prior to the closing.

The foregoing description of the Forfeiture Agreement does not purport to be complete and is qualified in its entirety by the terms and conditions of the Forfeiture Agreement, a copy of which is attached hereto as Annex F and is incorporated herein by reference.

Lock-Up Agreement

Concurrently with the execution of the Business Combination Agreement, ParentCo entered into a Lock-Up Agreement (“Lock-Up Agreement”) with Sponsor, and certain Liminatus